About PathCision Medicine

PathCision Medicine, Inc. is a biotechnology company founded in 2022 using tissue pathology insights to develop new targeted therapies. Built using a translational lens with a multi-omics approach, our proprietary discovery platform uncovers novel therapeutic avenues previously unavailable to patients with complex diseases. PathCision’s leading program is focused on developing a biologic modality for metastatic-selective delivery to tumors, improving patients’ quality of life through limiting toxicity.

We are strongly positioned at the intersection of drug candidate discovery using AI and ownership of promising therapeutic assets. Our initial focus is on metastatic cancers, which affect millions worldwide and currently have limited effective treatments, but we have conviction that our discovery platform and current assets are applicable to a variety of other diseases that are presently incurable.